InnoCare Pharma 诺诚健华(HKEX: 09969; SSE: 688428)

China · 110 Employees
InnoCare Pharma is a commercial stage biopharmaceutical company dedicated to discovering, developing, and commercializing best-in-class and/or first-in-class drugs for the treatment of cancer and autoimmune diseases. InnoCare has strong in-house innovation capabilities, holding multiple foreign and domestic patents with a rich product pipeline target liquid tumors, solid tumors, and autoimmune diseases. Our team has discovered and developed a strong pipeline, including one commercial drug BTK inhibitor orelabrutinib, 11 drug candidates on phase I/II/III clinical stage and 5 on IND-enabling stage. InnoCare was co-founded by Professor Shi Yigong, a world-renowned structural biologist, and Dr. Cui Jisong, an outstanding leader in the biopharmaceutical industry. We have near 900 employees. Our core R&D staff brings rich experience from the world's top pharmaceutical companies, such as Pfizer, GSK, Bristol-Myers Squibb, Merck, Johnson & Johnson, Bayer, etc. We are a truly global biopharmaceutical company with sites in Beijing, Nanjing, Shanghai, and Guangzhou, Hong Kong and Unites States. On March 23, 2020, InnoCare officially listed on the Hong Kong Stock Exchange (code: 9969). Our vision is to become a world-class biopharma leader to address the unmet medical needs globally.

概述

国家 China
成立时间 2013
总部 No. 8 Life Science Park Road, Beijing, Beijing Municipality, CN, 100084
电话号码 +86 10 6660 9999
网站 http://www.innocarepharma.com
LinkedIn http://www.linkedin.com/company/innocare-pharma
Twitter
Facebook
员工数 110
行业 research,
简介 InnoCare Pharma is a commercial stage biopharmaceutical company dedicated to discovering, developing, and commercializing best-in-class and/or first-in-class drugs for the treatment of cancer and autoimmune diseases. InnoCare has strong in-house innovation capabilities, holding multiple foreign and domestic patents with a rich product pipeline target liquid tumors, solid tumors, and autoimmune diseases. Our team has discovered and developed a strong pipeline, including one commercial drug BTK inhibitor orelabrutinib, 11 drug candidates on phase I/II/III clinical stage and 5 on IND-enabling stage. InnoCare was co-founded by Professor Shi Yigong, a world-renowned structural biologist, and Dr. Cui Jisong, an outstanding leader in the biopharmaceutical industry. We have near 900 employees. Our core R&D staff brings rich experience from the world's top pharmaceutical companies, such as Pfizer, GSK, Bristol-Myers Squibb, Merck, Johnson & Johnson, Bayer, etc. We are a truly global biopharmaceutical company with sites in Beijing, Nanjing, Shanghai, and Guangzhou, Hong Kong and Unites States. On March 23, 2020, InnoCare officially listed on the Hong Kong Stock Exchange (code: 9969). Our vision is to become a world-class biopharma leader to address the unmet medical needs globally.

技术

AddThis

Social Sharing

Bootstrap Framework

CSS and JavaScript Libraries

Google Tag Manager

Tag Management

Microsoft Azure Hosting

Hosting

Microsoft Office 365

Other

Mobile Friendly

Other

常见问题

InnoCare Pharma 诺诚健华(HKEX: 09969; SSE: 688428) 在哪里?

InnoCare Pharma 诺诚健华(HKEX: 09969; SSE: 688428) 的总部位于 No. 8 Life Science Park Road, Beijing, Beijing Municipality, CN, 100084

InnoCare Pharma 诺诚健华(HKEX: 09969; SSE: 688428) 的电话号码是多少?

InnoCare Pharma 诺诚健华(HKEX: 09969; SSE: 688428) 的电话号码是 +86 10 6660 9999

InnoCare Pharma 诺诚健华(HKEX: 09969; SSE: 688428) 的官方网站是什么?

InnoCare Pharma 诺诚健华(HKEX: 09969; SSE: 688428) 的公司官方网站是 http://www.innocarepharma.com

InnoCare Pharma 诺诚健华(HKEX: 09969; SSE: 688428) 是做什么的?

InnoCare Pharma 诺诚健华(HKEX: 09969; SSE: 688428) 的业务有哪些?

new drug discovery,medicinal chemistry,discovery biology,cmc,pharmacology,oncology diseases,autoimmune diseases,clinical development,medical research,biotechnology

InnoCare Pharma 诺诚健华(HKEX: 09969; SSE: 688428) 的年收入是多少?

InnoCare Pharma 诺诚健华(HKEX: 09969; SSE: 688428) 的收入是 208000美元

InnoCare Pharma 诺诚健华(HKEX: 09969; SSE: 688428) 有多少员工?

InnoCare Pharma 诺诚健华(HKEX: 09969; SSE: 688428) 有 110 名员工

InnoCare Pharma 诺诚健华(HKEX: 09969; SSE: 688428) 属于哪个行业?

InnoCare Pharma 诺诚健华(HKEX: 09969; SSE: 688428) 从事以下行业: research

InnoCare Pharma 诺诚健华(HKEX: 09969; SSE: 688428) 使用什么技术?

InnoCare Pharma 诺诚健华(HKEX: 09969; SSE: 688428) 使用的一些流行技术包括: AddThis,Bootstrap Framework,Google Tag Manager,Microsoft Azure Hosting,Microsoft Office 365,Mobile Friendly

如何联系 InnoCare Pharma 诺诚健华(HKEX: 09969; SSE: 688428)?

InnoCare Pharma 诺诚健华(HKEX: 09969; SSE: 688428) 联系信息: 电话号码:+86 10 6660 9999, 网站:http://www.innocarepharma.com, 邮箱:yuc***@***.com

InnoCare Pharma 诺诚健华(HKEX: 09969; SSE: 688428) 的社交媒体链接是什么?

InnoCare Pharma 诺诚健华(HKEX: 09969; SSE: 688428) 领英:http://www.linkedin.com/company/innocare-pharma,fackbook:,twitte:

InnoCare Pharma 诺诚健华(HKEX: 09969; SSE: 688428) 是一家上市公司吗?

是的,InnoCare Pharma 诺诚健华(HKEX: 09969; SSE: 688428)是一家上市公司,在sehk公开挂牌上市,上市交易代码:09969

InnoCare Pharma 诺诚健华(HKEX: 09969; SSE: 688428) 的最后一轮融资是什么时候?

暂无最近投资信息

谁投资 InnoCare Pharma 诺诚健华(HKEX: 09969; SSE: 688428)?

InnoCare Pharma 诺诚健华(HKEX: 09969; SSE: 688428) 有 0 家投资者,包括 。

管理层

Yucheng Pang

Associate Director of medicinal chemistry

Abbie Huang

Talent Acquisition Head

Bright Wang

VP of Corporate Affairs

Aixia Lu

Clinical Trial Operation Excellence Director

Serena Mika

Senior Clinical Project Manager

员工

Nghia Ba

Chief Executive Officer

Sean Zhang

Chief Medical Officer

Yang Gao

人力资源助理总监

Aimee Zhao

人力资源经理

外贸获客 查找关键决策人

10亿+海关交易数据,1.2亿企业数据,2亿+企业联系人数据,1000千万真实采购商。覆盖200+个国家及地区,95%外贸重点拓展市场,可根据行业、经营范围等多方位挖掘目标客户。
免费试用

Top-ranked on G2 Crowd

全球B2B企业库 海关贸易数据 展会采购数据

工作更少,成就更大,销售更聪明

查找更多 B2B 联系人,丰富并验证记录
Email Address

全球B2B企业库

海关贸易数据

展会采购数据

Top-ranked on G2 Crowd

OR
Sign Up with Google